VEGFA and hepatocellular carcinoma: In a retrospective study looking at advanced HCC patients who had received anti-PD1/PD-L1 followed by PBT within a month of the ICI, 12 patients were given a combination of ICIs with tyrosine kinase inhibitors, anti-VEGF, or other ICIs (4 with nivolumab plus sorafenib or lenvatinib; 6 with bevacizumab plus nivolumab or atezolizumab; and 2 with nivolumab plus ipilimumab), and 17 patients received anti-PD-1 monotherapy (15 nivolumab and 2 pembrolizumab).